Large Cap

AI-Driven Rally Set To Expand To Power, Commodities, Utilities: 'It's Not Just About Nvidia Anymore'
Why Is Dyne Therapeutics Stock Soaring On Monday?
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Why Is Dyne Therapeutics Stock Soaring On Monday?
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Medtronic's Heart Catheter Achieves Safety And Efficacy Goals In Patients With Irregular Heartbeat
Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute

Large Cap Recent News

What's Going On With European Airline Ryanair's Stock Today?
Ryanair Holdings reported full-year results with 25% revenue growth, 34% net profit increase, and plans for 8% traffic growth in FY25.
$60B TAM Target: CyberArk Bolsters Machine Identity Solutions With Venafi Acquisition
CyberArk Software Ltd. acquires Venafi from Thoma Bravo for $1.54 billion, adding $150 million in ARR and expanding TAM from $50 billion to $60 billion.
Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch
Gilead Sciences reports interim results from the ASSURE study of seladelpar in primary biliary cholangitis, showing significant improvements in cholestasis markers and pruritus.
Genetic Profile Key To Novo Nordisk's Wegovy's Weight-Loss Effectiveness, Study Reveals
Certain genes may predict strong responses to Novo Nordisk's Wegovy (semaglutide) in obesity treatment, with patients showing significant weight loss linked to a "hungry gut" genetic profile. This finding could enhance personalized obesity care, optimizing treatment outcomes.
What's New In Consumer Tech World Last Week? News That You Should Know (May 12-May 19, 2024)
Chinese chipmakers make headway in producing high bandwidth memory semiconductors, Zuckerberg celebrates 40th birthday on superyacht, Google may revive Google Glass, and Musk expresses skepticism about OpenAI's AI model development.
MicroStrategy Was The Best Among These 10 Large-Cap Stocks Scoring Big Last Week (May 12-May 19, 2024): Are They In Your Portfolio?
Top performing large-cap stocks in the last week: MSTR, MNDY, ONON, SE, PODD, DELL, VOD, ALC, SMCI, CRBG. Analysts raise price targets & more positive news.
Li Auto Was One Of The Worst-Performing Stocks Last Week: Are These 10 Large-Cap Stocks Losers In Your Portfolio? (May 12-May 18, 2024)
Last week, these 10 large-cap stocks had the worst performance. NICE, PBR, FIX, LI, MLM, VMC, BMRN, EDU, GFI, MUFG all saw significant decreases.
Wall Street Jumps Back To Record Highs, Dow Hits 40,000 As Inflation Fears Recede, Meme Stock Frenzy Returns: This Week In The Market
Major market indexes reached record highs for the fourth week in a row, fueled by inflation data and expectations for interest rate cuts. Meme stocks resurged, while Buffett bought Chubb and Dimon warned about fiscal deficit.
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine, and achieve a high single-digit CAGR from 2024 to 2029.
Fresenius SE's Future With Dialysis Company Unclear, Investors Seek Answers
Investors urge Fresenius SE to clarify its strategic plans for Fresenius Medical Care after recent deconsolidation. Despite holding a 32% stake, challenges like high dialysis patient mortality and nursing shortages impact both companies' performance and share value.
European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
Moderna wins a crucial legal battle at the European Patent Office against Pfizer and BioNTech over Covid-19 vaccine patents.
Pembina Pipeline's Cedar LNG On Track For Final Investment Decision In June: Details
Pembina Pipeline Corp announced progress on its Cedar LNG project and a 4%-6% growth in adjusted EBITDA per share & $2.2B-$4B in expenditures by 2026.
Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval
Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe menopausal vasomotor symptoms compared to placebo.

Explore Benzinga's Financial Tools

Find Stocks Tailored to Your Trading Interests
Find Stocks Tailored to Your Trading Interests
Benzinga Pro offers a real-time newsfeed as headlines break on earnings releases, analyst ratings, rumors, the biggest movers, and many more actionable alerts.

Compare Benzinga's Favorite Stock Brokers

Claim Exclusive Offers

Compare Benzinga's Favorite Cryptocurrency Brokers

Claim Exclusive Offers